GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00431617 | Liver | NAFLD | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/1882 | 412/18723 | 3.00e-13 | 1.75e-10 | 91 |
GO:00104987 | Liver | NAFLD | proteasomal protein catabolic process | 101/1882 | 490/18723 | 1.35e-12 | 6.09e-10 | 101 |
GO:0006517 | Liver | NAFLD | protein deglycosylation | 9/1882 | 26/18723 | 6.56e-04 | 8.50e-03 | 9 |
GO:00725947 | Liver | NAFLD | establishment of protein localization to organelle | 62/1882 | 422/18723 | 1.48e-03 | 1.64e-02 | 62 |
GO:0036507 | Liver | NAFLD | protein demannosylation | 6/1882 | 18/18723 | 6.55e-03 | 4.69e-02 | 6 |
GO:0036508 | Liver | NAFLD | protein alpha-1,2-demannosylation | 6/1882 | 18/18723 | 6.55e-03 | 4.69e-02 | 6 |
GO:001049812 | Liver | Cirrhotic | proteasomal protein catabolic process | 216/4634 | 490/18723 | 2.52e-21 | 9.29e-19 | 216 |
GO:007259412 | Liver | Cirrhotic | establishment of protein localization to organelle | 189/4634 | 422/18723 | 1.01e-19 | 2.45e-17 | 189 |
GO:00349767 | Liver | Cirrhotic | response to endoplasmic reticulum stress | 130/4634 | 256/18723 | 1.72e-19 | 3.86e-17 | 130 |
GO:004316112 | Liver | Cirrhotic | proteasome-mediated ubiquitin-dependent protein catabolic process | 184/4634 | 412/18723 | 4.52e-19 | 8.85e-17 | 184 |
GO:00066057 | Liver | Cirrhotic | protein targeting | 148/4634 | 314/18723 | 3.86e-18 | 6.20e-16 | 148 |
GO:00709724 | Liver | Cirrhotic | protein localization to endoplasmic reticulum | 45/4634 | 74/18723 | 4.79e-11 | 2.73e-09 | 45 |
GO:0030433 | Liver | Cirrhotic | ubiquitin-dependent ERAD pathway | 45/4634 | 85/18723 | 2.19e-08 | 7.75e-07 | 45 |
GO:00365032 | Liver | Cirrhotic | ERAD pathway | 53/4634 | 107/18723 | 2.58e-08 | 8.89e-07 | 53 |
GO:00725994 | Liver | Cirrhotic | establishment of protein localization to endoplasmic reticulum | 26/4634 | 46/18723 | 4.14e-06 | 6.94e-05 | 26 |
GO:00450474 | Liver | Cirrhotic | protein targeting to ER | 24/4634 | 42/18723 | 7.49e-06 | 1.15e-04 | 24 |
GO:00065171 | Liver | Cirrhotic | protein deglycosylation | 14/4634 | 26/18723 | 1.37e-03 | 9.14e-03 | 14 |
GO:00365071 | Liver | Cirrhotic | protein demannosylation | 10/4634 | 18/18723 | 5.00e-03 | 2.59e-02 | 10 |
GO:00365081 | Liver | Cirrhotic | protein alpha-1,2-demannosylation | 10/4634 | 18/18723 | 5.00e-03 | 2.59e-02 | 10 |
GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414114 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
hsa005104 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
hsa005134 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
hsa0414115 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
hsa0051011 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
hsa0051311 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
hsa0051021 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
hsa005132 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
hsa0414132 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
hsa0051031 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
hsa005133 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
hsa0414130 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
hsa005105 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
hsa005135 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
hsa04141113 | Oral cavity | OSCC | Protein processing in endoplasmic reticulum | 143/3704 | 174/8465 | 6.82e-26 | 2.28e-23 | 1.16e-23 | 143 |
hsa0051012 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
hsa0051312 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
hsa0414145 | Oral cavity | EOLP | Protein processing in endoplasmic reticulum | 70/1218 | 174/8465 | 2.84e-17 | 3.06e-15 | 1.81e-15 | 70 |
hsa0414155 | Oral cavity | EOLP | Protein processing in endoplasmic reticulum | 70/1218 | 174/8465 | 2.84e-17 | 3.06e-15 | 1.81e-15 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAN1A1 | SNV | Missense_Mutation | | c.838G>A | p.Glu280Lys | p.E280K | P33908 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MAN1A1 | SNV | Missense_Mutation | novel | c.1541G>A | p.Arg514Gln | p.R514Q | P33908 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAN1A1 | SNV | Missense_Mutation | novel | c.655G>A | p.Glu219Lys | p.E219K | P33908 | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAN1A1 | SNV | Missense_Mutation | rs199809553 | c.1913N>C | p.Leu638Pro | p.L638P | P33908 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAN1A1 | SNV | Missense_Mutation | | c.1122G>A | p.Met374Ile | p.M374I | P33908 | protein_coding | tolerated(0.2) | benign(0.156) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MAN1A1 | SNV | Missense_Mutation | | c.1567N>A | p.Ala523Thr | p.A523T | P33908 | protein_coding | deleterious(0.03) | probably_damaging(0.936) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MAN1A1 | SNV | Missense_Mutation | | c.1415N>A | p.Gly472Asp | p.G472D | P33908 | protein_coding | tolerated(0.57) | probably_damaging(1) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
MAN1A1 | SNV | Missense_Mutation | novel | c.1066N>C | p.Glu356Gln | p.E356Q | P33908 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAN1A1 | SNV | Missense_Mutation | novel | c.1019C>T | p.Ala340Val | p.A340V | P33908 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAN1A1 | SNV | Missense_Mutation | | c.1111G>A | p.Glu371Lys | p.E371K | P33908 | protein_coding | tolerated(0.12) | benign(0.022) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |